Multiple sclerosis is a demyelinating disease in which neurological deficits result from damage to myelin, axons, and neuron cell bodies. Prolonged or repeated episodes of demyelination impair remyelination. We hypothesized that augmenting Sonic hedgehog (Shh) signaling in chronically demyelinated lesions could enhance oligodendrogenesis and remyelination. Shh regulates oligodendrocyte development during postnatal myelination, and maintains adult neural stem cells. We used genetic approaches to detect Shh expression and Shh responding cells in vivo. Shh
Introduction
Multiple sclerosis (MS) is a demyelinating autoimmune disease that results in long term disability due to limited remyelination capacity and cumulative damage to axons (Dutta and Trapp, 2014) . Effective remyelination in MS cases has been demonstrated after early stage, or acute, demyelination and may correspond with symptom remission (Raine and Wu, 1993) . Relatively limited remyelination is observed in chronic MS, which is attributed to multiple factors including prolonged immune attack, axon damage, an insufficient oligodendrocyte regenerative response, and inhibitory conditions within the sclerotic lesion environment (Kuhlmann et al., 2008; Dutta and Trapp, 2011) . To complement immunosuppressive therapies, interventional strategies are sought to accelerate and/or promote the extent of remyelination to protect vulnerable demyelinated axons from further damage and to recover function of intact axons.
Pre-clinical studies in mice have shown that the cellular processes responsible for generating oligodendrocytes depend on the biological context, therefore developmental myelination and acute demyelination models may provide insights for optimization of oligodendrogenesis in chronic disease. Neural stem cells (NSCs) of the ventricular-subventricular zone (V-SVZ) contribute to postnatal myelination (Suzuki and Goldman, 2003; Tong et al., 2015) . NSCs generate oligodendrocyte progenitor (OP) cells that migrate into white matter regions, such as the corpus callosum, and continue to proliferate as well as differentiate into myelinating oligodendrocytes (Tripathi et al., 2011; Crawford et al., 2016; Sanchez and Armstrong, 2018) . In adulthood, much lower homeostatic levels of oligodendrogenesis are required to support myelin plasticity and maintenance (Menn et al., 2006; El Waly et al., 2014) . In response to acute demyelination, OP cells within the adult white matter proliferate to generate sufficient oligodendrocytes for efficient remyelination (Armstrong et al., 2002; Armstrong et al., 2006; Crawford et al., 2016) . OP cells continue to be present in chronically demyelinated lesions but exhibit reduced capacity for proliferation and differentiation, possibly due to the presence of inhibitory signals (Armstrong et al., 2006; Fancy et al., 2009; Zhou et al., 2012) .
The current studies examine the cellular response of the Sonic hedgehog (Shh) signaling pathway in the context of chronic demyelination. The Shh pathway has both the potential to serve as a marker of NSCs from the V-SVZ in normal adult mice, and the potential to regulate NSC and/or OP responses that impact remyelination (Ahn and Joyner, 2005; Ihrie et al., 2011; Ferent et al., 2013; Samanta et al., 2015) . Canonical Shh signaling is required for a postnatal wave of oligodendrogenesis from the V-SVZ (Tong et al., 2015) . Postnatal Shh responsive NSCs in the V-SVZ generate OP cells that populate the corpus callosum, persist into adulthood, and contribute to remyelination (Sanchez and Armstrong, 2018) . In healthy adult mice, NSCs in the V-SVZ exhibit active Shh signaling (Ahn and Joyner, 2005) . However, Shh signaling is down regulated with differentiation along the oligodendrocyte lineage (Ihrie et al., 2011; Mierzwa et al., 2014; Samanta et al., 2015) . Indeed, genetic reporter mice demonstrate a stark absence of canonical Shh signaling among all cell types in the adult corpus callosum (Ihrie et al., 2011; Mierzwa et al., 2014; Samanta et al., 2015) . Furthermore, canonical Shh signaling through Gli1 appears to inhibit NSC mobilization from the V-SVZ into the corpus callosum after acute demyelination (Samanta et al., 2015) . However, NSC recruitment from the V-SVZ may not be required in this acute demyelination condition; remyelination of acute lesions is mainly carried out by amplification of OP cells that populated the corpus callosum during postnatal myelination (Kazanis et al., 2017) .
To discriminate potential beneficial or detrimental effects of Shh signaling relative to repair of chronic demyelination, we examined the Shh pathway during adult homeostasis and during progressive stages of cuprizone (CPZ) demyelination. In vivo Shh signaling at specific time points was detected by inducing heritable genetic labeling of cells actively transcribing Shh or Gli1. Gli1 transcription is an effective readout for canonical Shh signaling (Ahn and Joyner, 2005) . Shh CreERT2 mice or
Gli1
CreERT2 mice were crossed either to R26 tdTomato mice to label cells with red fluorescence, or, to R26 IAP mice to label membranes with alkaline phosphatase. Time points throughout the progression of acute through chronic demyelination were analyzed, as well as after remyelination. Finally, we delivered a Hedgehog (Hh) pathway agonist of the Smoothened receptor into the chronically demyelinated region of the corpus callosum to evaluate Gli1 activation, the regenerative response, and remyelination capacity. This combination of approaches revealed novel insights of Hh signaling in vivo during the progression of acute through chronic demyelination, and the potential for modulating Hh signaling to enhance remyelination of chronic lesions.
Methods

Mice for genetic inducible fate labeling
Mice were housed and cared for in accordance with the guidelines of the National Institutes of Health and the Institutional Animal Care and Use Committee of the Uniformed Services University of the Health Sciences. Shh CreERT2/+ (B6.129S6-Shh tm2(cre/ERT2)Cjt /J; 005623; Jackson Laboratories; Bar Harbor, ME) or Gli1 CreERT2/+ (Gli1 tm3(cre/ESR1)Alj /J; 007913; Jackson Laboratories; provided by Dr. Sohyun Ahn, National Institutes of Health) mice express Cre recombinase fused to a mutated estrogen receptor, which requires tamoxifen (TMX) binding for nuclear translocation (Ahn and Joyner, 2004; Harfe et al., 2004; Ahn and Joyner, 2005 (Madisen et al., 2010) . The R26 IAP reporter mouse line expresses the human alkaline phosphatase (AP) gene, with a floxed inverted exon 2 (Badea et al., 2009) . TMX (T5648; Sigma; St. Louis, MO) was dissolved in corn oil (C8267; Sigma) to a concentration of 20 mg/ ml and was administered via oral gavage (10 mg/day) on two consecutive days to induce Cre recombination and reporter expression in cells transcribing Shh or Gli1.
Demyelination with cuprizone
First generation crosses were used as heterozygotes for the promoter and reporter alleles for Gli1
CreERT2
; R26 tdTomato , Gli1
; R26 IAP ,
Shh
CreERT2
; R26 tdTomato or Shh
; R26 IAP mice. At 8 weeks of age, male mice were given chow containing 0.3% CPZ for 3 or 6 weeks to induce acute demyelination in the corpus callosum or for 12 weeks to induce chronic demyelination. Some cohorts were returned to normal chow to follow fate-labeled cells without CPZ present. The specific experimental design for each cohort is shown with the results. Only male mice were used for demyelination due to toxicity effects of CPZ in C57BL/6 J female mice that results in the disruption of the estrus cycle and prevents analysis of gender differences (Taylor et al., 2010) .
Immunohistochemistry and reporter detection
Mice were perfused with 3% paraformaldehyde and brains were further post fixed in 3% paraformaldehyde overnight. Coronal brain sections, 14 μm thick, were used for immunohistochemistry and/or reporter detection for all studies. Thicker 20 μm sections were used to improve detection of fine processes in Shh CreERT2 ; R26 IAP tissue.
Antibodies used for immunolabeling are detailed in Table 1 . Myelin was immunostained for myelin oligodendrocyte glycoprotein (MOG) (Linington and Lassmann, 1987; Breithaupt et al., 2003) . Cell typespecific immunolabeling used Iba1 for microglia, glial fibrillary acidic protein (GFAP) for white matter astrocytes, and Olig2 for oligodendrocyte lineage cells, with more specific labeling with NG2 for OP cells and GSTpi for oligodendrocytes. The tdTomato reporter signal was visible without additional processing. AP activity was detected as previously described (Mierzwa et al., 2014) . Briefly, endogenous AP activity was deactivated by incubating mounted brain sections in heated phosphate buffer saline (69°C for 90 min). Sections were then incubated in nitro-blue tetrazolium chloride (NBT)/5-bromo-4-chloro-3-indoly-phosphate toluidine salt (BCIP) substrate (K0598; DAKO/Agilent; Santa Clara, CA) overnight and then incubated in methyl green for nuclear staining (SP5000; Vector Laboratories; Burlingame, CA).
Cell proliferation in vivo
Ki67 antigen detection (Table 1 ) was used to identify cells in an active stage of cell division at the time of perfusion. Biotinylated secondary antibody was detected using an ABC kit (PK-6101; Vector Laboratories) followed by brown diaminobenzidine chromogen reaction Vector Laboratories) R26 tdTomato mice received EdU (100 mg/kg) over five days with twice daily injections given 2 h apart (10 injections in total) starting approximately 2 h after SAG or vehicle delivery (see below). EdU was detected in tissue sections using a Click-iT ® Plus EdU kit (C10637; Thermo Fisher Scientific).
Hedgehog agonist administration
Smoothened agonist SAG (566,661; InSolution™ Smoothened Agonist, EMD Millipore Sigma; Burlington, MA) was microinjected into the corpus callosum as previously described (Mierzwa et al., 2014) . Briefly, chronically demyelinated Gli1
CreERT2
;R26 tdTomato mice were anesthetized with isofluorane and placed in a stereotaxic frame to drill a small hole in the skull for microinjection. A 10-μl Hamilton syringe (7653-01; Hamilton Company, Reno, NV) with removable needle (RN) compression fitting adapters (55750-01; Hamilton Company) was used to mount a pulled glass pipette (outer diameter 50 mm) and microinject 1 μl of SAG (SAG; 10 μM) or vehicle (NDC 0409-4888-10; 0.9% sodium chloride INJ, USP, Hospira; Lake Forest, IL) into the posterior corpus callosum (1.0 mm posterior to bregma, 0.5 mm to the right of midline and 1.3 mm deep). Each microinjection was completed over a 5 min period. The needle was left in place for 1 min to reduce backflow along the needle track. The skin was closed using Tissumend II SC (3,006,178; Veterinary Products Laboratories, Phoenix, AZ).
Image acquisition, quantification and statistical analysis
Fluorescent images were acquired using a SPOT RT3 camera (Diagnostic Instruments, Sterling Heights, MI) or a Zeiss LSM 700 (Carl Zeiss Microscopy, Thornwood, NY). Images of AP and Ki67 chromogen reactions were acquired using a NanoZoomer 2.0-RS (Hamamatsu Instruments, Hamamatsu, Japan). Quantification included 3 coronal tissue sections per animal with at least 3 animals per group, unless otherwise specified. Quantitative analysis focused on the caudal region of the corpus callosum and overlying cortical regions between approximately −0.94 to −1.58 mm from bregma (Franklin and Paxinos, 1997) , where CPZ demyelination is prominent (Xie et al., 2010) . For quantification purposes, the regions-of-interest in these caudal coronal sections were defined for the corpus callosum as extending from the midline to the inner wall of the lateral ventricle, and for the cerebral cortex as extending from the midline to the lateral end of cingulum. Spot Advanced Software (http://www.spotimaging.com; RRID: SCR_ 014313; Spot imaging solutions, Sterling Heights, MI) was used to measure the area of each region-of-interest. The areas of MOG immunolabeling in the corpus callosum were estimated based on the number of pixels with intensities above the background intensity level using the thresholding function in MetaMorph software (https://www. moleculardevices.com; RRID: SCR_002368; Molecular Devices, Downingtown, PA). Cells labeled with tdTomato, NG2, GSTpi or EdU were quantified as cells/mm 2 . Additional qualitative analysis included coronal tissue sections within this caudal region as well as a rostral region between 0.14 and −0.22 mm from bregma. High resolution images were acquired on a Zeiss 700 confocal microscope.
Figures were prepared as panels using Adobe Photoshop version 7.0 or above (http://www.adobe.com; RRID: SCR_014199; Mountain View, CA). Prism 7.01 (http://www.graphpad.com; RRID: SCR_002798; Graphpad; San Diego, CA) was used to prepare graphs and perform statistical analyses. Both quantitative and qualitative analyses were performed blinded and the number of mice included in each analysis is listed in each figure legend. Acute demyelination and astrocyte reactivity were analyzed using one-way analysis of variance followed by Tukey's post hoc test. Two-way analysis of variance was used for cell density values in the corpus callosum and in the cortex. Sidak's multiple comparisons test was used for post hoc analysis. Quantification is presented as mean ± standard error of the mean. Statistical significance was set as p < 0.05. 
Gli1
CreERT2 mice and reporter lines were backcrossed to the C57BL/ 6 J genetic background prior to feeding with 0.3% CPZ. As previously characterized, microglia and astrocytes exhibit a dynamic neuroinflammatory response throughout progressive stages of CPZ demyelination (Hibbits et al., 2012) . Gli1 CreERT2 mice exhibited microglial activation ( Fig. 1 ) and astrogliosis ( Fig. 2 ) similar to our prior studies in C57BL/6 J mice. Gli1
CreERT2
; R26 tdTomato mice were given TMX at 3 weeks of CPZ prior to early demyelination ( Fig.1A -D) to coincide with robust microglial activation, as assessed by immunolabeling for the microglial activation marker Iba1 ( Fig. 1E -G). After TMX, mice were allowed to survive for a subsequent 2 week period without CPZ to provide time for cells transcribing Gli1 to undergo recombination and express the tdTomato reporter ( Fig Shh responsive cells were next examined toward the end of the acute demyelination period and the fate of Gli1-labeled cells was followed into the remyelination period (Fig. 2) . Gli1
CreERT2 mice were crossed to the R26 IAP reporter line to take advantage of the AP membrane localization, which can reveal myelin-like membrane formation during remyelination (Sanchez and Armstrong, 2018) . Gli1
CreERT2 ;
R26
IAP mice given TMX after 5 weeks of CPZ were perfused on week 6 of CPZ to provide one week for AP reporter expression and to assess demyelination at the end of CPZ treatment ( Fig. 2A ). An additional cohort of mice survived for a 3 week period after the end of CPZ to follow Gli1 fate-labeled cells during early remyelination ( Fig. 2A) . Immunolabeling of myelin showed extensive demyelination of the corpus callosum after 6 weeks of CPZ and extensive remyelination after the 3 week recovery period (Fig. 2B-D, N) . Reactive astrogliosis, detected by GFAP immunolabeling, was prevalent in the corpus callosum at 6 weeks of CPZ and persisted at a lower level after a 3 week recovery period ( Fig. 2E-J removing CPZ from the diet. Gli1 expressing AP labeled (Gli1-AP) astrocytes were prominent in the cortex of healthy adults and after CPZ ( Fig. 2K-M) . In contrast, the corpus callosum was absent of Gli1-AP cells in healthy adults (Fig. 2K) , at the peak of demyelination (Fig. 2L ), or during remyelination (Fig. 2M ). This absence of Gli1-AP cells in the corpus callosum after TMX induction at 3 (Fig. 1 ) or 5 weeks (Fig. 2) of CPZ ingestion demonstrates that canonical Shh signaling was not detectable in activated microglia or reactive astrocytes during acute demyelination. In addition, the OP cell population in the corpus callosum expands several-fold at 5-6 weeks of CPZ (Armstrong et al., 2006; Davidson et al., 2017) yet OP cells were not Gli1 fate-labeled when TMX was administered during week 5 of CPZ and mice were followed through early remyelination (Fig. 2M) . Shh signaling is known to regulate the NSC population in adult V-SVZ (Ahn and Joyner, 2005; Ihrie et al., 2011) . Therefore, NSCs of the V-SVZ were examined as a potential Shh responsive population that may be recruited into the adjacent corpus callosum after acute demyelination (Fig. 3) . In Gli1
CreERT2
; R26 tdTomato mice with TMX induction at 3 weeks of CPZ, Gli1-Tom cells were localized in the V-SVZ, particularly in ventral regions but were not observed in the corpus callosum ( Fig. 3A-C) . Similarly, in Gli1
; R26 IAP mice given TMX at 5 weeks of CPZ, Gli1-AP cells were observed in the V-SVZ (Fig. 3D-F) . Gli1 fate-labeled oligodendrocytes were very rarely observed in the corpus callosum (Fig. 3F) . age-matched to the longer time point. Dashes outline the corpus callosum (CC). B-D: MOG immunohistochemistry was used to detect myelin, which is present throughout the corpus callosum in controls (B). The MOG immunolabeled area was reduced after 6 weeks of CPZ, due to extensive demyelination (C), and normalized after remyelination during the 3 week recovery period without CPZ (D). E-G: Normal GFAP immunolabeling of astrocytes in the corpus callosum of control mice (E), compared to increased GFAP immunolabeling after acute demyelination (F), which was only partially attenuated after a 3 week recovery period (G) Insets of higher magnification to show GFAP pattern in healthy white matter (E) and after demyelination (F), with persistent change during recovery period (F). H-J: Co-localization of demyelination with astrogliosis is illustrated in merged images of the MOG and GFAP immunolabeling. K-M: The same Gli1 CreERT2 ; R26 IAP mice analyzed by MOG and GFAP immunohistochemistry had proximate sections examined for alkaline phosphatase reporter expression (dark blue), with nuclear counterstain (cyan). Gli1 fate-labeled (Gli1-AP) cells were observed in cortical regions but not in the adjacent corpus callosum in healthy control mice (K), after acute demyelination (L), or following remyelination (M). Quantification of the immunolabeling for MOG (N) and GFAP (O) shows the progression of corpus callosum pathology and recovery. Quantification and representative images from no CPZ (n = 3), 6 wks CPZ (n = 3), and 6 wks CPZ + 3 wks (n = 4). Scale bar in B and K = 200 μm, in E inset = 50 μm.
Gli1 expressing cells localize within the corpus callosum after chronic demyelination but do not contribute to remyelination
To investigate whether Shh signaling may change after chronic demyelination, Gli1
CreERT2
; R26 tdTomato mice were fed chow containing CPZ for 12 weeks. At the end of CPZ, mice were administered TMX and then switched to normal chow for 2 weeks to examine the fate of Shh responsive cells after a short recovery interval (Fig. 4A ). In the agematched control mice without CPZ, MOG immunohistochemistry shows myelin throughout the corpus callosum of Gli1
; R26 tdTomato mice (Fig. 4B ). These 22-week old control mice did not have Gli1 fate-labeled cells in the corpus callosum (Fig. 4C ), in agreement with our prior studies with TMX given in adult mice (Mierzwa et al., 2011; Sullivan and Armstrong, 2017) . As expected, the chronic CPZ mice showed loss of MOG immunolabeling, which confirmed demyelination (Fig. 4D) . Surprisingly, the tdTomato reporter showed Gli1 expressing (Gli1-Tom) cells localized within the chronically demyelinated corpus callosum (Fig. 4E ). Gli1-Tom cells were not oligodendrocyte progenitors or oligodendrocytes based on the oligodendrocyte lineage marker Olig2 (Fig. 4F ). Gli1-Tom cells were identified as reactive astrocytes in the chronically demyelinated corpus callosum based on morphology and immunolabeling with GFAP (Fig. 4G) . Gli1
; R26 IAP mice served as a second reporter line to evaluate
Gli1 fate-labeled cells in the corpus callosum after chronic CPZ. Gli1
; R26 IAP mice were fed CPZ for 12 weeks, administered TMX at the end of CPZ, and then analyzed after a 6 week recovery period without CPZ to determine whether AP labeled myelin-like membranes during remyelination (Fig. 5) . Indeed, AP reporter expression showed Gli1-AP cells in the corpus callosum after chronic demyelination ( Fig. 5B-C) . The Gli1-AP cells in the corpus callosum had thick processes consistent with the morphology of reactive astrocytes ( Fig. 5C and inset). Gli1-AP cells did not extend thin, myelin-like membranes along axons (see Sanchez and Armstrong, 2018) . Our initial analysis focused on caudal regions of the corpus callosum, where demyelination is most prominent (Xie et al., 2010) . Compared to caudal regions in chronic CPZ mice, Gli1-AP cells were less frequently observed in the corpus callosum at rostral levels adjacent to the V-SVZ, which is a site of Gli1 fate-labeled NSCs in adults ( Fig. 5D-F) . Proliferating cells immunolabeled by Ki67 were present without Gli1 fate-labeling in the corpus callosum (Fig. 5F ). Gli1-AP cells were not observed with nuclear Ki67, although Ki67 immunolabeling may have been obscured in Gli1-AP cells with a strong substrate reaction. However, throughout the V-SVZ, Ki67 immunolabeled actively proliferating cells were detected with and without Gli1 fate-labeling ( Fig. 5G and inset) . ; R26 tdTomato mice were administered TMX to detect Shh synthesis in healthy adults, during active demyelination, and after chronic demyelination (Figs. 6, 7) . Shh expressing AP labeled cells (Shh-AP) were not observed within the corpus callosum in healthy adult mice ( Fig. 6A-E) , during acute demyelination (Fig. 6F-J) , or after chronic demyelination ( Fig. 6K-O) . Shh fate-labeling identified neurons as the major source of Shh based on neuroanatomical distribution and morphology (Figs. 6-7) . Shh-AP cells with neuronal morphology were distributed within the cerebral cortex and in ventral brain regions. Shh-AP labeled axons were consistently detected superficial to the medial corpus callosum, and rarely within the corpus callosum (Fig. 6) . Overall, Shh-AP labeling appeared similar across the three time points (Fig. 6 ). These patterns of Shh-AP and Shh-Tom cells are consistent with our prior study with TMX given to adult healthy mice which also showed co-labeling for the neuronal marker NeuN (Sullivan and Armstrong, 2017). given TMX after 5 weeks of CPZ and continued on CPZ through 6 weeks followed by a subsequent 3 week recovery period on normal chow without CPZ (D). Gli1-AP cells were prevalent in dV-SVZ and vV-SVZ domains (E). Gli1-AP cells were rarely found in the corpus callosum (F), with an example of an oligodendrocyte shown (F, inset). Representative images from Gli1 CreERT2 ;
Active Shh transcription is not detected in cells within
R26
tdTomato mice (n = 3) and Gli1 CreERT2 ; R26 IAP mice (n = 4). Scale bar in B = 500 μm, C = 200 μm, E = 500 μm, F = 100 μm.
Smoothened agonist enhances remyelination in corpus callosum after chronic demyelination
These experiments show a lack of local Shh expression in the corpus callosum during acute or chronic demyelination. However, this result leaves open the question of whether Shh, if available, could regulate cellular responses in the chronic lesion environment. A small molecule agonist, SAG, was used to test the effect of augmenting signaling through Shh or other Hh family members in the corpus callosum of chronically demyelinated mice. SAG is an agonist of the Smoothened receptor, which activates Hh signaling through both canonical and noncanonical pathways (Briscoe and Therond, 2013) . SAG was microinjected into the corpus callosum of Gli1
CreERT2 ; R26 tdTomato mice after chronic demyelination with CPZ (Fig. 8A) . EdU, a thymidine analogue, was administered daily for five days to label cycling cells. TMX was administered on days 2 and 3 after CPZ to fate-label Gli1 expressing cells. Mice were perfused for analysis after a 10 day recovery period without CPZ. Parallel age-matched control Gli1 CreERT2 ; R26 tdTomato mice, without CPZ or injections, did not have Gli1-Tom cells in the corpus callosum (n = 2; not shown), which agrees with the No CPZ examples in Fig. 4B -C. After chronic CPZ, Gli1-Tom cells are present in the corpus callosum in both SAG and vehicle conditions (Fig. 8B ). Gli1-Tom cells are reduced in the ipsilateral corpus callosum in both conditions indicating an effect of the injection procedure (Fig. 8B) . Rare Gli1-Tom cells with highly branched thin processes, characteristic of oligodendrocytes (Murtie et al., 2005) , were detected adjacent to the V-SVZ (Fig. 8C ). Gli1-Tom cells mainly appeared to be cortical astrocytes, as are found in healthy adults (Fig. 8D ) (Garcia et al., 2010) . Gli1-Tom cells were less frequent within the corpus callosum (Fig. 8D) . Cell type-specific immunolabeling was used to examine the response to SAG injection among cells with and without Gli1 fate-labeling ( Fig. 8D-P) . OP cells immunolabeled for NG2 were not Gli1 fate-labeled in the cortex or in the corpus callosum ( Fig. 8D-E) . EdU labeled cycling cells were observed within the cortex and corpus callosum, including NG2 cells, but these cells were not Gli1 fate-labeled ( Fig. 8D-E) . SAG increased EdU labeling in the cortex, which included cycling OP cells labeled with NG2 and EdU (Fig. 8F-G) . In the corpus callosum, overall EdU incorporation and cycling OP cells with NG2 and EdU labeling were increased ipsilateral to the injection and the highest values were observed with SAG delivery (Fig. 8H-I ). The total NG2 population was not changed with SAG or vehicle injection (Fig. 8J) . However, NG2 cells may go on to differentiate into oligodendrocytes and so could be lost from the NG2 pool, resulting in normalized population levels. Immunolabeling for MOG showed a significant increase in the myelinated Fig. 4 . Gli1 fate-labeled cells localize within the corpus callosum after chronic demyelination. A: Gli1
CreERT2 ; R26 tdTomato mice were fed cuprizone (CPZ) for 12 weeks to induce chronic demyelination. Tamoxifen (TMX) was administered at the end of CPZ to fate-label Gli1 expressing cells, which were analyzed 2 weeks later. B-C: Without CPZ, MOG immunolabeling detected myelin throughout the corpus callosum (B). Gli1 fate-labeled (Gli1-Tom) cells were absent in the corpus callosum (CC) of agematched control (No CPZ) mice (C). D-E: After chronic CPZ, MOG immunolabeling showed extensive demyelination (D) and a low density of Gli1-Tom cells localized within the corpus callosum (D, E; examples at arrows). F-G: The Gli1-Tom population is distinct from oligodendrocyte lineage cells identified by nuclear Olig2 immunoreactivity (F; arrows denote same Gli1-Tom cell pair). Astrocytes are Gli1-Tom labeled in the corpus callosum based on GFAP immunolabeling within the cell body and/or processes (G; arrows). A minority of Gli1-Tom cell in the cortex are double labeled for GFAP (G, arrowhead). Panel G is generated from a confocal stack of optical images to capture cell processes. Representative images from No CPZ (n = 2) and CPZ (n = 2). Scale bar in B = 200 μm, G = 20 μm.
area of the corpus callosum, which demonstrated a positive effect of SAG on remyelination after chronic CPZ (Fig. 8K-M) . Consistent with enhanced remyelination, SAG increased oligodendrocytes, which were identified by GSTpi, but this change was not statistically significant ( Fig. 8N-O) . SAG increased oligodendrocytes and MOG in both the ipsilateral and contralateral corpus callosum, which is consistent with spreading of the injection volume in the plane of axons and bilateral effects of corpus callosum injections of SAG or retrovirus in our prior studies (Murtie et al., 2005; Mierzwa et al., 2014) . The majority of Gli1-Tom cells in the corpus callosum were reactive astrocytes, based on morphology and GFAP immunolabeling (Fig. 8P ). These results demonstrate that SAG enhanced remyelination even though active Shh signaling through Gli1 was not detected in NG2 and GSTpi cells, or in other cell types within the corpus callosum. These results may indicate that SAG enhanced remyelination through the non-canonical Hh pathway, either directly and/or indirectly through other cell types in the corpus callosum.
Discussion
These studies demonstrate differences in Shh signaling during the cellular response to acute versus chronic demyelination, and the potential for non-canonical Hh signaling to stimulate proliferation and increase remyelination after chronic demyelination. Specifically, we show that acute CPZ demyelination did not induce canonical Shh signaling, i.e. Gli1 fate-labeling, in activated microglia, reactive astrocytes, or OP cells that generate oligodendrocytes for remyelination. Only chronic demyelination resulted in Gli1 fate-labeled Shh responsive cells in the corpus callosum. Importantly, delivery of SAG, a Hh pathway agonist, into the chronically demyelinated corpus callosum increased proliferation and remyelination. However, SAG delivery did not induce Gli1 fate-labeling, raising the possibility that non-canonical Hh signaling may be a mechanism for beneficial SAG effects after chronic demyelination.
The presence of Gli1 fate-labeled cells in the corpus callosum after chronic demyelination is in contrast with the lack of Gli1 fate-labeling in the corpus callosum of healthy adults and in acute demyelination conditions, which were examined for comparison. Canonical Shh signaling, detected by Gli1 fate-labeling, acts mainly in NSCs of the ventral V-SVZ to generate olfactory bulb interneurons in healthy adult brain (Ihrie et al., 2011) . Gli1 fate-labeling was only rarely detected in the corpus callosum of healthy adults, consistent with the low level of oligodendrocytes generated from the V-SVZ (Garcia et al., 2010; Ihrie et al., 2011) . Gli1 fate-labeling was also rarely detected in the corpus callosum after acute demyelination (Samanta et al., 2015) . Therefore, specific factors associated with the chronic demyelination condition may alter the corpus callosum lesion environment to influence the generation and/or recruitment of Gli1 fate-labeled cells.
Gli1 fate-labeled cells in the chronically demyelinated corpus callosum may be derived from several sources. Gli1 fate-labeled cells may be endogenous cells in the corpus callosum that activate Gli1 transcription in the chronic lesion context, presumably due the longer duration of demyelination or due to different molecular signals in the lesion environment. However, Gli1 fate-labeled cells within the corpus callosum were not increased by local delivery of SAG. Two major cell populations, NSCs of the V-SVZ and a subpopulation of cortical astrocytes, exhibit high Gli1 expression and thus could be a source of Gli1 fate-labeled cells. Chronic demyelination could possibly increase recruitment of Gli1 fate-labeled cells from these sites outside of the corpus callosum. Importantly, Gli1 fate-labeled cells in the chronically demyelination corpus callosum are mainly reactive astrocytes. Further studies may provide insights as to whether canonical Shh signaling contributes to the recruitment and/or transition of reactive astrocytes in the formation of sclerotic lesion conditions in chronic demyelinating disease.
In addition to exploiting Gli1 CreERT2 mice to monitor Shh responsive cells, the current studies are the first to use complementary Shh CreERT2 mice to evaluate changes in Shh synthesis during the course of acute and chronic demyelination. Neuronal cell types synthesize Shh in the cerebral cortex, septal regions, and ventral forebrain in healthy adult mice (Alvarez-Buylla and Ihrie, 2014) . Upregulated Shh expression in glial cells has been reported using a variety of other techniques. Shh immunolabeling was upregulated in oligodendrocytes in acute demyelinated lesions of the corpus callosum resulting from lysolecithin Fig. 5 . Cells fate-labeled for Gli1 after chronic demyelination persist in the corpus callosum through remyelination. A: Gli1 CreERT2 ; R26 IAP mice were given cuprizone (CPZ) for 12 weeks to induce chronic demyelination. Tamoxifen (TMX) was administered at the end of CPZ to fate-label Gli1 expressing (Gli1-AP) cells, which were analyzed 6 weeks later. B-C: In caudal sections, Gli1-AP cells were found at high density in the cerebral cortex and in ventral regions (B) while present at a low density in the corpus callosum (CC)(C). Enlarged view of morphology of Gli1-AP cells in the corpus callosum (C, inset). D-G: In rostral sections containing the ventricular-subventricular zone (V-SVZ), Gli1-AP cells localized within the corpus callosum less frequently than in caudal sections (D-F). Proliferating cells in the corpus callosum were labeled by Ki67 were often found without AP labeling for Gli1 expression (F). In the V-SVZ, Gli1-AP cells were found in dorsal and ventral domains (E). Proliferating KI67 labeled cells were also found throughout the V-SVZ, especially in the dorsal (dV-SVZ) region (G). KI67 labeled cells with and without Gli1 fate-labeling in the V-SVZ (G, inset). Representative images from Gli1
CreERT2
; R26 IAP mice (n = 3). Scale bar for B = 800 μm; C = 100 μm; D = 800 μm; E = 300 μm; F = 150 μm and G = 200 μm.
M.A. Sanchez et al. Neurobiology of Disease 115 (2018) 145-156 injection (Ferent et al., 2013) . After cortical injury in adult mice, interleukin-1β from activated microglia/macrophage cells was reported to induce Shh immunolabeling of reactive astrocytes (Amankulor et al., 2009) . However, Shh immunolabeling may detect Shh binding to reactive astrocytes in lesion areas (Samanta et al., 2015) . In contrast, using quantitative array analysis, we did not find an increase of Shh mRNA transcript levels in the corpus callosum throughout stages of acute and chronic CPZ demyelination (Hibbits et al., 2012) . Our analysis in Shh CreERT2 mice utilizes Shh promoter activity for gene-specific analysis of Shh expression in acute and chronic demyelination. An early demyelination stage was examined at 3 weeks of CPZ feeding based on our prior work showing prominent microglial activation along with an approximately 10-fold elevation of interleukin-1β transcript levels in the corpus callosum (Hibbits et al., 2012) . The current study confirmed robust microglial activation after 3 weeks of CPZ yet Shh fate-labeling was not observed in cells within the corpus callosum in Shh CreERT2 mice.
In agreement with this result, Shh levels were not sufficient to activate Gli1 fate-labeling of corpus callosum cells after acute demyelination.
Furthermore, Shh synthesis was not observed in cells within the corpus callosum after chronic CPZ demyelination, or in age-matched healthy control Shh CreERT2 mice. However, analysis of the role of Shh ligands is complicated by the potential activity of other Hh family ligands and by the ability of the Hh ligands to act through short and long distance mechanisms, including secretion in extracellular vesicles (Gradilla et al., 2014; Vyas et al., 2014) . Experimental modulation to activate or inhibit Shh signaling can identify Shh roles in the generation and regeneration of glial cells in adult mice. Genetic conditional activation of Shh signaling in NSCs of the V-SVZ expanded the NSC pool but depleted the generation of direct progeny, including oligodendrocyte lineage cells in the corpus callosum of healthy adult mice (Ferent et al., 2014) . Therefore, low levels of Shh activation may need to be maintained in the V-SVZ for oligodendrocyte and myelin homeostasis. Recent studies of Shh signaling in acute demyelination models have involved relatively small corpus callosum lesions, either from lysolecithin injection (Ferent et al., 2013) or from 0.4% CPZ in mice of a non-C57BL/6 genetic background (Samanta et al., 2015) . In acute demyelinated lesions, mRNA transcripts for key Shh signaling components, Gli1 and Smoothened, have been reported as upregulated in oligodendrocytes and microglia, respectively (Ferent et al., 2013) . In addition, adenoviral-mediated overexpression of Shh increased remyelination in the adjacent corpus callosum, while an opposite effect was observed with overexpression of a Shh pathway antagonist (Ferent et al., 2013) . These Shh effects may be acting through NSCs in the V-SVZ, since adenovirus was delivered into the lateral ventricle to drive expression in ependymal cells. However, broader genetic and pharmacological inhibition of Shh signaling, specifically through Gli1, enhanced NSC mobilization from the V-SVZ and promoted remyelination of acute lesions in the corpus callosum (Samanta et al., 2015) . These studies present an inconsistent interpretation of the role of Shh signaling in acute demyelination models. As a simple, direct test of Shh effects on cellular responses after chronic demyelination, we microinjected SAG into the corpus callosum. SAG is an agonist of the Smoothened receptor, which mediates canonical and type II non-canonical Hh signaling initiated by multiple Hh family ligands (Brennan et al., 2012; Briscoe and Therond, 2013) . In our prior study in healthy adult mice, SAG microinjection into the corpus callosum increased Gli1 fate-labeled cells in the adjacent V-SVZ but not in cells of the corpus callosum (Mierzwa et al., 2014) . However, the current results show that the corpus callosum exhibits recruitment and/ or local activation of Gli1 expressing cells after chronic demyelination. Thus, SAG may have the potential to enhance cellular responses through Hh signaling after chronic demyelination. Indeed, we observed that SAG injection increased cell proliferation and remyelination in the corpus callosum. Additionally, SAG injection had a positive, but nonsignificant effect, of increasing cycling OP cells and oligodendrocytes. Surprisingly, SAG enhanced remyelination without increasing Gli1 expression in any cell types within the chronically demyelinated corpus callosum.
The specific mechanism of how SAG increased remyelination cannot be determined from the current studies. Our results are compatible with SAG acting as an agonist of type II non-canonical Hh signaling to enhance remyelination after chronic demyelination. However, SAG could act through canonical Shh signaling that was not detected for technical reasons. Additional time points or different TMX dosing may have detected more Gli1 fate-labeled cells. Furthermore, detailed studies of SAG interactions with the Smoothened receptor would be required to delineate the intracellular Hh signaling response in specific cell types after chronic demyelination, and to rule out potential off-target effects. In vivo genetic approaches are now warranted for analysis of non-canonical Hh signaling, specifically alternatives within the type II non-canonical pathway that involves Smoothened exclusive of Gli-dependent transcription (Brennan et al., 2012) . Additionally, Shh signaling is also known to modulate blood-brain barrier function and the immune response Sirko et al., 2013) so further studies that utilize immune mediated models of chronic demyelination are also needed to better understand the potential benefits of augmenting Shh signaling in chronic multiple sclerosis lesions.
Conclusions
These results demonstrate the potential to enhance remyelination by endogenous cells through modulation of Hh signaling, and reveal differences in population dynamics in chronic lesions. Shh transcription does not appear to be upregulated in cells within demyelinated lesions. However, cells with active canonical Shh signaling begin to localize within areas of chronic demyelination, which is not observed during adult homeostasis or during acute demyelination. This canonical Shh response may initiate in NSCs and could indicate a source of potential cells to repopulate lesions. Gli1 fate-labeling may be a useful tool for further in vivo studies to redirect differentiation to inhibit reactive astrogliosis and favor remyelination of chronic lesions. Furthermore, our results demonstrate that Gli1 expression in oligodendrocyte lineage Fig. 7 . Chronic cuprizone demyelinates the cerebral cortex and corpus callosum without marked changes in Shh fate-labeled cells. A: Shh CreERT2 ; R26 tdTomato mice were given cuprizone (CPZ) for 12 weeks to induce chronic demyelination followed by tamoxifen (TMX) administration at the end of CPZ and a 2 week period without CPZ. This shorter 2 week recovery period after CPZ shows Shh expression at the same time point as the Gli1 fate-labeling in Fig. 4 . CreERT2 ; R26 tdTomato mice after 12 weeks of cuprizone (CPZ) to induce chronic demyelination. EdU was also administered at the end of CPZ for five consecutive days to label cycling cells. Tamoxifen (TMX) was administered on days 2 and 3 after the end of CPZ to fate-label cells actively transcribing Gli1; mice were perfused 10 days after the end of CPZ. B-E: After chronic CPZ, Gli1 expressing (Gli1-Tom) cells are found in the corpus callosum in SAG and vehicle injected mice (B-E, red arrows). The number of Gli1-Tom cells was reduced in the area of the corpus callosum ipsilateral to the injection (B). Gli1-Tom cells in the corpus callosum included cells with mature oligodendrocyte morphology adjacent to the dorsal ventricular-subventricular zone (dV-SVZ) (C, white arrows). EdU labeling showed proliferating cells in the cerebral cortex and corpus callosum (D, blue arrows), some of which were oligodendrocyte progenitor (OP) cells identified by immunolabeling with NG2 (E, blue arrows). F-G: In the cortex, EdU labeling of proliferating cells in the cortical area ipsilateral to the injection was significantly higher in SAG than in vehicle injected mice (F). SAG significantly increased the number of proliferating OP cells (NG2 EdU double labeled cells) in the ipsilateral versus contralateral cortex (G). H-P: In the corpus callosum, EdU (H) and NG2 EdU doubled labeled cells (I) were significantly higher in the area of the corpus callosum ipsilateral to the injection, with the highest values observed in SAG mice. No difference was detected among total NG2 labeled cells in the corpus callosum across conditions (J). Immunohistochemistry to detect myelin oligodendrocyte glycoprotein (MOG) shows enhanced remyelination of the corpus callosum in mice given SAG vs vehicle (K-M). Remyelination was significantly higher in the corpus callosum ipsilateral to SAG injection (M). Oligodendrocytes, identified by GSTpi immunolabeling, were generally not among Gli1-Tom cells (N) or specifically an EdU labeled population (N, inset). Quantification of GSTpi cells shows an increase of oligodendrocytes with SAG injection, but this difference is not statistically significant (O). Gli1-Tom cells in the corpus callosum often had the morphology of reactive astrocytes (P) and were immunolabeled with the astrocytic marker GFAP (P). The inset is generated from a confocal stack of optical images to capture GFAP and tdTomato in cell processes (P, inset). Quantification and representative images from SAG (n = 7); Vehicle (n = 5). Scale bar in C = 100 μm; D = 200 μm; E = 50 μm; K and L, shown in L = 200 μm; N = 200 μm; P = 100 μm.
cells was not required for SAG to enhance remyelination. Therefore, SAG can promote remyelination after chronic demyelination and further studies are important to examine the therapeutic potential of noncanonical Hh signaling.
